Advanced search
Instruments
| Name | Stock exchange | Average volume | Price | Type | ||
|---|---|---|---|---|---|---|
| LYNCH GROUP HOLDINGS LIMITED | LGL | Australian S.E. | 27,724 |
1.31
AUD
 | Stock | |
| THOMAS WYATT NIGERIA PLC | THOMASWY | Nigerian S.E. | 115,217 |
1.8
NGN
| Stock | |
| THOMAS COOK (INDIA) LIMITED | THOMASCOOK | Bombay S.E. +1 Other | 108,655 |
201.8
INR
| Stock | |
| THOMAS COOK (INDIA) LIMITED | THOMASCOOK | NSE India S.E. | 1,706,210 |
202
INR
| ||
| MERRILL LYNCH DEPOSITOR INC. 6.0518% INDEX PLUS TRUST SERIES 2003-1 | IPB | Nyse | 1,338 |
25.33
USD
| Stock | |
| ETC - MERRILL LYNCH AFRICA LIONS INDEX | CPLCI | Swiss Exchange | - |
437
CHF
| Certificat | |
| ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX CANSLIM MEETS LYNCH | Börse Stuttgart | - | - EUR
| Certificat | ||
| ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX DOPPEL-MOMENTUM NACH LYNCH | Börse Stuttgart | - |
142.2
EUR
| Certificat | ||
| ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX DOPPEL-MOMENTUM NACH LYNCH | LS9QVU | Berne S.E. | - | - CHF
| Certificat | |
| THOMAS C 3.8/JUL23 | Deutsche Boerse AG | - | - %
| Obligation | ||
| MERRILL LYNCH S.A. IL TRIGGER RED NTS 27/03/37 | 87KO | London S.E. | - | - %
| Obligation |
News (2966)
Companies (51)
Christian Dior SE is a holding company organized around 6 areas of activity: - sale of fashion products and leather goods (48.9% of net sales): primarily Louis Vuitton, Fendi, Céline, Loewe, Givenchy, Kenzo, Thomas Pink, Berluti, Pucci and Loro Piana bra ...
Christian Dior SE is a holding company organized around 6 areas of activity: - sale of fashion products and leather goods (48.9% of net sales): primarily Louis Vuitton, Fendi, Céline, Loewe, Givenchy, Kenzo, Thomas Pink, Berluti, Pucci and Loro Piana bra ...
Daimler Truck Holding AG is specialized in designing, manufacturing and marketing trucks and buses. The business activity is structured around 4 areas: - medium and heavy truck sales: Mercedes-Benz, Fuso, Freightliner, Western Star and BharatBenz brands; ...
Daimler Truck Holding AG is specialized in designing, manufacturing and marketing trucks and buses. The business activity is structured around 4 areas: - medium and heavy truck sales: Mercedes-Benz, Fuso, Freightliner, Western Star and BharatBenz brands; ...
Ingersoll Rand Inc. specializes in the design, manufacture and marketing of industrial technological equipment. The group provides compressed air equipment (screw compressors, reciprocating compressors, centrifugal compressors, air dryers, air filters, et ...
Grupo Bimbo SAB de CV is a Mexico-based company engaged in the food processing sector. The Company focuses on the manufacture, distribution and sale of bread, breakfast bread muffins and bagels, frozen bread, cakes and smaller cakes, sweet and non-sweet c ...
Grupo Bimbo SAB de CV is a Mexico-based company engaged in the food processing sector. The Company focuses on the manufacture, distribution and sale of bread, breakfast bread muffins and bagels, frozen bread, cakes and smaller cakes, sweet and non-sweet c ...
Fairfax Financial Holdings Limited is a Canada-based holding company. The Company, through its subsidiaries, is engaged in property and casualty insurance and reinsurance and the associated investment management. The Companyâs segments include Property ...
Fairfax Financial Holdings Limited is a Canada-based holding company. The Company, through its subsidiaries, is engaged in property and casualty insurance and reinsurance and the associated investment management. The Companyâs segments include Property ...
Fairfax Financial Holdings Limited is a Canada-based holding company. The Company, through its subsidiaries, is engaged in property and casualty insurance and reinsurance and the associated investment management. The Companyâs segments include Property ...
Insiders
Thomas J.
Lynch's current job(s) include Senior VP-Compliance, Regulatory & Public Affairs at Grifols Therapeutics, Inc. since 2011 and Senior VP-Compliance, Regulatory & Public Affairs at Talecris Biotherapeutics Holdings Corp.
since 2011.
Dr. Lynch's former job(s) include Director at Haemacure Corp.
from 2008 to 2013, Deputy Director-Hematology Division at the US Food & Drug Administration, VP-Regulatory Affairs & Quality Assurance at Artivion, Inc. in 2005, Senior VP-Regulatory Affairs & Quality Assurance at Clearant, Inc. from 2000 to 2003, and Research Scientist at the National Institutes of Health.
Dr. Lynch's education history includes a doctorate degree from Wayne State University (Michigan) and a graduate degree from Georgetown University.
Thomas A.
Lynch is currently a Senior Vice President at Southern Nuclear Operating Co. He completed his undergraduate degree at The University of New Mexico and his graduate degree at the University of Oklahoma in 1992.
Thomas J.
Lynch served as Chief Human Resources Officer & Vice President at PPL Corp.
from 2016 to 2022.
Prior to that, he was Senior Vice President-Human Resources at New WEI, Inc. from 2012 to 2015 and Vice President-Human Resources at NRG Energy, Inc. in 2010-2011.
Lynch holds an undergraduate degree from State University of New York College at Oswego and a graduate degree from New York Law School.
Thomas James Lynch is currently the President & Director at Fred Hutchinson Cancer Research Center.
He is also a Director at Seattle Cancer Care Alliance and a Director at The Schwartz Center for Compassionate Healthcare.
Additionally, he serves as an Independent Director at Foghorn Therapeutics, Inc. and as a Non-Executive Director at Hummingbird Bioscience Pte Ltd.
Dr. Lynch is a Member of the American Society of Clinical Oncology, Inc., the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.
Formerly, Dr. Lynch served as the Chairman & Chief Executive Officer at Massachusetts General Physician's Organization, Inc. from 2015 to 2017.
He was also the Chairman at Kleo Pharmaceuticals, Inc. from 2019 to 2020.
Additionally, he served as an Independent Director at Infinity Pharmaceuticals, Inc. from 2009 to 2014 and as the Director & Professor at Yale Cancer Center from 2009 to 2015.
Dr. Lynch was the Director at Massachusetts General Hospital Cancer Center from 2015 to 2017 and the Chief Scientific Officer & Executive VP at Bristol Myers Squibb Co. from 2017 to 2019.
He also held positions at PearlPoint Cancer Support, Inc., The General Hospital Corp., Harvard Medical School, and Yale School of Medicine.
Dr. Lynch holds a doctorate degree from Yale University.
Thomas P.
Lynch worked as Secretary, Chief Legal & Compliance Officer at Nuwellis, Inc. from 2018 to 2021.
Prior to that, he was Senior Legal Counsel at Novartis Corp.
from 2012 to 2015 and Secretary, Chief Administrative Officer & EVP at Orexigen Therapeutics, Inc. from 2017 to 2018.
Lynch also served as Head-Legal & Compliance at Novartis Pharma AG.
Lynch received his undergraduate degree from Stanford University, his graduate degree from the University of St. Thomas, and his graduate degree from Boston College Law School.
No results for this search
- Stock Market
- Advanced search
- Thomas Lynch